|1.||Sedo, Aleksi: 10 articles (01/2015 - 03/2004)|
|2.||Reinhold, Dirk: 10 articles (01/2012 - 01/2006)|
|3.||Kajiyama, Hiroaki: 10 articles (02/2010 - 05/2002)|
|4.||Kikkawa, Fumitaka: 10 articles (02/2010 - 05/2002)|
|5.||Ino, Kazuhiko: 10 articles (02/2010 - 05/2002)|
|6.||Mizutani, Shigehiko: 10 articles (02/2010 - 05/2002)|
|7.||Shibata, Kiyosumi: 10 articles (02/2010 - 05/2002)|
|8.||Morimoto, Chikao: 9 articles (01/2014 - 09/2002)|
|9.||Ansorge, Siegfried: 8 articles (01/2012 - 01/2006)|
|10.||Ohnuma, Kei: 7 articles (01/2014 - 03/2005)|
|1.||Type 2 Diabetes Mellitus (MODY)
05/01/2015 - "This work aimed to compare the efficacy of dipeptidyl peptidase-IV (DPP-4) inhibitors and their impact on β-cell function in Asian and Caucasian patients with type 2 diabetes mellitus. "
11/01/2015 - "Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. "
09/01/2015 - "One of the new approaches to the management of type 2 diabetes mellitus (T2DM) consists of orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitors. "
01/01/2015 - "There have only been a few reports about use of dipeptidyl peptidase 4 (DPP-4) inhibitors in elderly patients with type 2 diabetes mellitus (T2DM), suggesting that the safety of these agents has not been sufficiently demonstrated. "
12/01/2014 - "Dipeptidyl peptidase 4 (DPP4) inhibitors have been widely used in the treatment of type 2 diabetes mellitus. "
12/01/2012 - "Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis."
01/01/2015 - "The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. "
10/01/2015 - "To determine whether the combination of dipeptidyl-peptidase 4 (DPP-4) inhibitors vs. sulfonylureas with metformin after failure of first-line treatment is associated with a decreased risk for major adverse cardiovascular events (myocardial infarction and stroke) and for all-cause mortality. "
02/15/2015 - "The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) are unclear. "
11/01/2002 - "Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients."
08/01/2015 - "Dipeptidyl peptidase IV (DPP-IV) expression in visceral adipose tissue is reportedly increased in obese patients, suggesting an association of DPP-IV with inflammation. "
09/01/2014 - "Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats."
07/05/2014 - "The direct effects of dipeptidyl peptidase-IV (DPP-IV) inhibitors on endoplasmic reticulum (ER) stress-induced apoptosis and inflammation in cardiomyocytes have not been elucidated. "
01/01/2014 - "Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model."
11/01/2013 - "Dipeptidyl peptidase 4 (DPP4) inhibitors, used in obese diabetic patients, reduce inflammation in several models. "
01/01/2014 - "This study was performed to evaluate whether a dipeptidyl peptidase IV (DPP IV) inhibitor is effective in improving TAC-induced diabetes mellitus by reducing pancreatic islet injury. "
02/01/2015 - "Tissue-specific dipeptidyl-peptidase 4 (DPP4) dysregulation has been described in adults with diabetes mellitus. "
01/01/2015 - "Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)-piperazin-2-one), is a new dipeptidyl peptidase IV inhibitor used for the treatment of type II diabetes mellitus. "
01/01/2013 - "Dipeptidyl peptidase 4 (DPP4) inhibitors are used for treatment of diabetes mellitus (DM). "
09/01/2012 - "Dipeptidyl peptidase IV (DPP4) is an important target for the treatment of type II diabetes mellitus. "
09/10/2015 - "In a similar way, dipeptidyl peptidase IV (DPP-IV) showed to have favorable effects in animal models of ischemia/reperfusion. "
01/01/2014 - "This protocol describes the preconditioning of the liver in a dipeptidyl peptidase-IV (DPPIV(-))-deficient rat model of efficient repopulation utilizing a selective external beam irradiation technique combined with regional transient portal ischemia (RTPI). "
01/01/2014 - "We investigated whether attenuating dipeptidyl peptidase-IV (DPP4) enzyme activity protected rat heart from ischemia-reperfusion (IR) injury (40-min left anterior descending coronary artery ligation followed by 72 h reperfusion). "
04/01/2015 - "Sitagliptin, a dipeptidyl peptidase-IV inhibitor, was recently shown to improve cognitive functions in diabetic rats; hence the present study was conducted to evaluate its protective effect against transient ischemia-reperfusion (I/R) in diabetic animals. "
01/01/2013 - "We hypothesized that dipeptidyl peptidase-IV (DPP4) may impair angiogenesis, endothelial function, and the circulating number of endothelial progenitor cells (EPC) in a model of critical limb ischemia (CLI) through ligating the left femoral artery using DPP4-deficient rats. "
|2.||CD13 Antigens (Alanine Aminopeptidase)
|4.||Glucagon-Like Peptide 1 (GLP 1)
|6.||Peptide Hydrolases (Proteases)
|4.||Transplantation (Transplant Recipients)